Kim Anna Reiss

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Peripheral blood immune correlates associated with TGF-β inhibition (galunisertib) and stereotactic body radiotherapy (SBRT) in patients with advanced hepatocellular carcinoma (HCC).”.

Peripheral blood immune correlates associated with TGF-β inhibition (galunisertib) and stereotactic body radiotherapy (SBRT) in patients with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4575

N/A

0DataRank · unranked

0 citations

Kim Anna Reiss, Michael A. Giannone, Nevena Damjanov, Elizabeth Prechtel Dunphy, Lisa Dicicco +8 more

A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA- or PALB2-related pancreatic cancer who have progressed on rucaparib.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4131

N/A

0DataRank · unranked

2 citations

Mark H. O’Hara, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, Natallia Izgur +4 more

APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation—ECOG-ACRIN EA2192.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps763

N/A

0DataRank · unranked

8 citations

Sung Chul Hong, Anup Kasi, Eileen M. O’Reilly, Shishir K. Maithel, Xin Yao +10 more

Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4198

N/A

0DataRank · unranked

6 citations

Katherine A. Guthrie, Michael J. Pishvaian, Kim Anna Reiss, Andrew M. Lowy, Davendra Sohal +7 more

Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4202

N/A

0DataRank · unranked

3 citations

Sung Chul Hong, Anup Kasi, Eileen M. O’Reilly, Shishir K. Maithel, Xin Yao +10 more

The identification of reversion mutations in patients with advanced pancreatic cancer and germline or somatic BRCA or PALB2 variants who were treated with maintenance rucaparib.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.734

N/A

0DataRank · unranked

1 citations

Arielle Yablonovitch, Jennifer Yen, Lesli A. Kiedrowski, Erica L. Carpenter, Katherine L. Nathanson +3 more